Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
An initial study of Ubamatamab (MUC16xCD3) in patients with advanced Low-Grade Serous Ovarian Cancer (LGSOC) demonstrated a 73% objective response rate and 11-month median progression-free survival. LGSOC is a distinct ovarian cancer variant with limited treatment options and generally lower responsiveness to conventio
Regeneron said ubamatamab (MUC16xCD3) showed a high rate of durable responses in an initial study of patients with advanced low-grade serous ovarian cancer.